Literature DB >> 9890110

Indications for, and use of, cytotoxic agents in SLE.

J H Klippel1.   

Abstract

Over the past decade, cytotoxic drugs have come to assume an increasingly important role in the management of systemic lupus erythematosus. Intravenous cyclophosphamide has become the standard treatment for lupus affecting major organs, in particular lupus nephritis. Cytotoxics with less potential for adverse side effects such as azathioprine and methotrexate are widely used in the management of non-major organ lupus and as an adjunct to reduce corticosteroid requirements. Recent clinical experience in lupus with newer cytotoxic drugs such as cyclosporin A, adenosine analogues, and mycophenolate mofetil appear promising and may offer improvements in lupus management in the future.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9890110     DOI: 10.1016/s0950-3579(98)80033-2

Source DB:  PubMed          Journal:  Baillieres Clin Rheumatol        ISSN: 0950-3579


  3 in total

1.  High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial.

Authors:  Michelle Petri; Robert A Brodsky; Richard J Jones; Douglas Gladstone; Michael Fillius; Laurence S Magder
Journal:  Arthritis Rheum       Date:  2010-05

2.  Belimumab in systemic lupus erythematosus: an update for clinicians.

Authors:  Susan S Kim; Kyriakos A Kirou; Doruk Erkan
Journal:  Ther Adv Chronic Dis       Date:  2012-01       Impact factor: 5.091

Review 3.  Newer drugs for the treatment of lupus nephritis.

Authors:  Dudy G Kuiper-Geertsma; Ronald H W M Derksen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.